[1]Kuznetsova E, Schliebs R. β-Amyloid, Cholinergic Transmission, And Cerebrovascular System-A Developmental Study In A Mouse Model Of Alzheimer's Disease. Curr Pharm Des. 2013. [Epub ahead of print]
[2]Nivsarkar M, Banerjee A. Establishing the probable mechanism of L-DOPA in Alzheimer's disease management. Acta Pol Pharm. 2009; 66(5):483-486.
[3]Lagoja I, Pannecouque C, Griffioen G, et al. Substituted 2-aminothiazoles are exceptional inhibitors of neuronal degeneration in tau-driven models of Alzheimer's disease. Eur J Pharm Sci. 2011; 43(5):386-392.
[4]Prakash A, Medhi B, Chopra K. Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-β induced experimental model of Alzheimer's disease. Pharmacol Biochem Behav. 2013; 110C:46-57.
[5]Masoodi TA, Al Shammari SA, Al-Muammar MN, et al. Exploration of deleterious single nucleotide polymorphisms in late-onset Alzheimer disease susceptibility genes. Gene. 2013; 512(2):429-437.
[6]Nizzari M, Thellung S, Corsaro A, et al. Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signaling. J Toxicol. 2012; 2012: 187297.
[7]Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2009;106 (16):6820-6825.
[8]Revett TJ, Baker GB, Jhamandas J, et al. Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci. 2012; 37(5):110190.
[9]Viswanathan J, Haapasalo A, Böttcher C, et al. Alzheimer's disease-associated ubiquilin-1 regulates presenilin-1 accumulation and aggresome formation. Traffic. 2011; 12(3):330-348.
[10]Depboylu C, Lohmüller F, Du Y, et al. Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease. Neurosci Lett. 2006; 400(3):187-190.
[11]Nicoll AJ, Panico S, Freir DB, et al. Amyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity. Nat Commun. 2013;4(1):2416.
[12]Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012; 488(7409):96-99.
[13]Lee JE, Han PL. An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp Neurobiol. 2013; 22(2):84-95.
[14]Beauquis J, Pavía P, Pomilio C, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease.Exp Neurol. 2013 ;239:28-37.
[15]IAbdalla S, Langer A, Fu X, et al. ACE Inhibition with Captopril Retards the Development of Signs of Neurodegeneration in an Animal Model of Alzheimer's Disease. Int J Mol Sci. 2013; 14(8):16917-16942.
[16]Eketjäll S, Janson J, Jeppsson F, et al. AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice. J Neurosci. 2013; 33(24):10075-10084.
[17]Nilsen LH, Melø TM, Saether O, et al. Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study. J Neurochem. 2012; 123(4):532-541.
[18]Katsouri L, Vizcaychipi MP, McArthur S, et al. Prazosin, an α(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23transgenic mouse model of Alzheimer's disease. Neurobiol Aging. 2013;34(4):1105-1115.
[19]Nizzari M, Thellung S, Corsaro A, et al. Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signaling. J Toxicol. 2012; 2012: 187297.
[20]Toda T, Noda Y, Ito G, et al. Presenilin-2 mutation causes early amyloid accumulation and memory impairment in a transgenic mouse model of Alzheimer's disease. J Biomed Biotechnol. 2011:2011:617974.
[21]Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000; 25:402-405.
[22]Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science.2001;293:1487-1491.
[23]Bhaskar K, Hobbs GA, Yen SH,et al. Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathol Appl Neurobiol. 2010; 36(6):462-477.
[24]赵晓燕,王丹丹,单烨,等. APP/PS1转基因鼠脑内小泛素化修饰物-1上调可能参与阿尔茨海默病老年斑形成和神经突起变性的调节[J].生理学报, 2013, 65(3): 253-262.
[25]邱昕, 陈国华, 汪弢, 等. 黄连解毒汤对APP/PS1双转基因阿尔茨海默病小鼠自由基代谢及海马区病理形态学影响[J]. 中国中西医结合杂志, 2011,31(10): 1379-1382.
[26]Yao ZG, Zhang L, Liang L, et al. The effect of PN-1, a Traditional Chinese Prescription, on the Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease. Evid Based Complement Alternat Med. 2013; 2013:518421.
[27]Neumeister KL, Riepe MW. Bupropion and Citalopram in the APP23 Mouse Model of Alzheimer's Disease: A Study in a Dry-Land Maze. Int J Alzheimers Dis. 2012; 2012:673584.
[28]Lee JE, Han PL. An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp Neurobiol. 2013; 22(2):84-95.
[29]Rantamäki T, Kemppainen S, Autio H,et al. The Impact of Bdnf Gene Deficiency to the Memory Impairment and Brain Pathology of APPswe/PS1dE9 Mouse Model of Alzheimer's Disease. PLoS One. 2013; 8(7):e68722.
[30]Li L, Zhang S, Zhang X, et al. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease. Curr Alzheimer Res. 2013; 10(4):433-441.
[31]Saadipour K, Yang M, Lim Y, et al. Amyloid beta1-42 (Aβ42) up-regulates the expression of sortilin via the p75NTR /RhoA signaling pathway. J Neurochem. 2013. [Epub ahead of print]
[32]Kim TK, Lee JE, Park SK, et al. Analysis of differential plaque depositions in the brains of Tg2576 and Tg-APPswe/PS1dE9 transgenic mouse models of Alzheimer disease. Exp Mol Med. 2012;44:492-502.
[33]McLean D, Cooke MJ, Albay R 3rd, et al. Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-β in TgCRND8 mice. ACS Chem Neurosci. 2013; 4(4):613-623.
[34]Nilsson LN, Bales KR, DiCarlo G, et al. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21(5):1444-1451.
[35]Salminen A, Kaarniranta K, Kauppinen A, et al. Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome.Prog Neurobiol. 2013; 106-107:33-54.
[36]Sahara N, Vega IE, Ishizawa T, et al. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins. J Neurochem. 2004;90(4):829-838.
[37]Olabarria M, Noristani HN, Verkhratsky A, et al. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia. 2010;58:831-838.
[38]Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003; 39:409-421.
[39]Overk CR, Perez SE, Ma C, et al. Sex steroid levels and AD-like pathology in 3xTgAD mice. J Neuroendocrinol. 2013; 25(2):131-144.
[40]Marques SC, Lemos R, Ferreiro E, et al. Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice. Neuroscience. 2012; 220:256-266.
[41]Peters OM, Shelkovnikova T, Tarasova T, et al. Chronic Administration of Dimebon does not Ameliorate Amyloid-β Pathology in 5xFAD Transgenic Mice. J Alzheimers Dis. 2013;36(3):589-596. |